Imarsa (Fulvestrant)

Fulvestrant acts on estrogen‑driven breast cancer pathways and is indicated for advanced disease management.

• Metastatic estrogen receptor‑positive breast cancer: reduces tumor growth and disease progression.
• Hormone receptor‑positive advanced breast cancer: offers an alternative after prior endocrine therapy failure.
• Postmenopausal women with ER‑positive disease: provides estrogen receptor degradation to control cancer spread.

• Fulvestrant binds competitively to the ligand‑binding domain of the estrogen receptor (ER) with high affinity, inducing a conformational change that targets the receptor for proteasomal degradation. This results in down‑regulation of ER protein levels, abolishing estrogen‑mediated transcription and proliferative signaling in ER‑positive tumor cells.

Common Side Effects

• Injection site pain: mild to moderate discomfort at the injection site.
• Hot flashes: transient sensation of warmth.
• Nausea: occasional upset stomach.
• Fatigue: general tiredness.
• Arthralgia: joint aches.
• Headache: mild to moderate.

Serious or Rare Side Effects

• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Pulmonary embolism: sudden shortness of breath or chest pain.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Tumor pain: worsening pain at metastatic sites.
• Hypercalcemia: elevated calcium levels causing confusion or weakness.
• QT interval prolongation: cardiac rhythm disturbance.

Before initiating therapy, consider the following precautions:

• Liver function monitoring: assess hepatic enzymes regularly.
• Thromboembolic risk assessment: evaluate history of clotting disorders.
• Hypersensitivity evaluation: check for known allergy to fulvestrant or excipients.
• Bone health: use caution in patients with severe osteoporosis.
• Pregnancy avoidance: contraindicated in pregnancy; ensure effective contraception.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Fulvestrant may interact with other medicines; review patient medication lists.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase fulvestrant exposure.
• Strong CYP3A4 inducers (e.g., rifampin): may reduce efficacy.
• Concurrent estrogen‑containing therapies: antagonistic effect.

Moderate Interactions (Monitor Closely)

• Warfarin: monitor INR for altered anticoagulation.
• Statins metabolized by CYP3A4: observe for increased statin levels.
• Antihypertensives: watch for blood pressure changes.
• Herbal supplements (e.g., St. John's wort): may affect metabolism.
• Anticoagulants: assess bleeding risk.